MedPath

Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Phase 1
Active, not recruiting
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2020-06-01
Last Posted Date
2024-02-01
Lead Sponsor
Sadat City University
Target Recruit Count
100
Registration Number
NCT04410341
Locations
🇪🇬

Faculty of Medicine, Shibīn Al Kawm, Egypt

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Phase 4
Withdrawn
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2020-05-14
Last Posted Date
2020-10-19
Lead Sponsor
Alto Neuroscience
Registration Number
NCT04388202

Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits

Phase 4
Completed
Conditions
Major Depression
Interventions
First Posted Date
2020-04-20
Last Posted Date
2023-12-29
Lead Sponsor
Emory University
Target Recruit Count
18
Registration Number
NCT04352101
Locations
🇺🇸

Emory Clinic, Atlanta, Georgia, United States

The Role of Serotonin in Compulsive Behavior in Humans: Underlying Brain Mechanisms

Phase 4
Active, not recruiting
Conditions
Obsessive-Compulsive Disorder/High Compulsive Individuals
Healthy Individuals
Interventions
Drug: Placebo oral tablet
First Posted Date
2020-04-07
Last Posted Date
2024-12-18
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
46
Registration Number
NCT04336228
Locations
🇩🇰

Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

Phase 4
Recruiting
Conditions
Anxious Depression
Depression
Interventions
First Posted Date
2020-01-29
Last Posted Date
2024-08-29
Lead Sponsor
University of Cincinnati
Target Recruit Count
84
Registration Number
NCT04245748
Locations
🇺🇸

University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

Phase 4
Recruiting
Conditions
Anxiety
Depressive Symptoms
Interventions
First Posted Date
2020-01-29
Last Posted Date
2024-08-29
Lead Sponsor
University of Cincinnati
Target Recruit Count
60
Registration Number
NCT04245436
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Serotonergic Modulation of Cognition, Emotion and Brain Activation in Healthy Volunteers

Phase 4
Completed
Conditions
Healthy
Interventions
First Posted Date
2020-01-27
Last Posted Date
2023-11-18
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
66
Registration Number
NCT04239339
Locations
🇩🇰

Neurobiology Research Unit, Copenhagen, Denmark

Canadian Biomarker Integration Network for Depression (CAN-BIND) - Validation Study

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2019-11-14
Last Posted Date
2023-03-02
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
1
Registration Number
NCT04162522
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

🇨🇦

University of British Columbia, Vancouver, British Columbia, Canada

🇨🇦

Queen's University, Kingston, Ontario, Canada

and more 3 locations

The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression

Not Applicable
Not yet recruiting
Conditions
Major Depressive Disorder
Interventions
Drug: Escitalopram+golimumab
Dietary Supplement: Escitalopram+Calcium Tablet
First Posted Date
2019-11-07
Last Posted Date
2020-05-12
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
180
Registration Number
NCT04156425

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

Not Applicable
Completed
Conditions
Major Depressive Disorder
Interventions
First Posted Date
2019-08-28
Last Posted Date
2022-10-12
Lead Sponsor
Sadat City University
Target Recruit Count
80
Registration Number
NCT04069819
Locations
🇪🇬

Faculty of Medicine, Shibīn Al Kawm, Egypt

© Copyright 2025. All Rights Reserved by MedPath